FindMyKOL
Clinical trialNCT07545317RecruitingObservational

Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

NCT07545317 is an observational study sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. As of 18 Nov 2026, it is recruiting participants. It studies IL-23 inhibitor and TNF inhibitors in Crohn's Disease. The registry lists an enrollment of 665 participants at 1 site in 1 country. The registry lists a start date of 16 Apr 2026 and a primary completion date of 31 Aug 2027. One of its registered investigators has a FindMyKOL profile.

SponsorSixth Affiliated Hospital, Sun Yat-sen UniversityEnrollment665Crohn's Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07545317
FieldValue
Registry IDNCT07545317
StatusRecruiting
Study typeObservational study
Lead sponsorSixth Affiliated Hospital, Sun Yat-sen University
Enrollment665
Registered sites1
Countries1
ConditionsCrohn's Disease
DrugsIL-23 inhibitor and TNF inhibitors
Start16 Apr 2026
Primary completion31 Aug 2027
Study completion31 Aug 2028
Last update posted9 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this observational study is to learn about the effectiveness and safety of IL-23 inhibitors in adults with active Crohn's disease in real-world clinical practice. The main questions it aims to answer are: * What proportion of participants achieve clinical remission at Week 12 after starting treatment with an IL-23 inhibitor? * What are the clinical, endoscopic, biomarker, imaging, and safety outcomes during induction and maintenance treatment? This is not a head-to-head randomized study. Treatments are selected by treating physicians as part of routine clinical care. For a nested comparative analysis, bio-naive participants treated with IL-23 inhibitors will be compared with a concurrent prospective cohort of bio-naive participants treated with TNF inhibitors to evaluate comparative effectiveness and safety. Participants will: * Receive treatment chosen by their treating physicians as part of routine clinical care, including IL-23 inhibitors or TNF inhibitors * Attend study follow-up visits during induction and maintenance, including assessments at baseline, Week 12 and Week 52 * Undergo routine clinical evaluations, which may include symptom assessment, laboratory tests, endoscopy, and imaging, as available * Be monitored for adverse events and treatment changes during the study * Optionally provide blood, stool, and other available samples for exploratory biomarker, microbiome, metabolomic, and other multi-omics analyses related to treatment response

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • the Sixth Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong

    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IL-23 inhibitorTNF inhibitors
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07545317

Each answer restates registry values shown on this page.

What is NCT07545317?

NCT07545317 is an observational study sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. It studies IL-23 inhibitor and TNF inhibitors in Crohn's Disease.

Is NCT07545317 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT07545317?

The registry names Wei Wang, MD (principal investigator, Sixth Affiliated Hospital, Sun Yat-sen University) as the overall official.

Where does NCT07545317 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT07545317 study?

The registered drug and biological interventions are IL-23 inhibitor and TNF inhibitors.

When is NCT07545317 expected to complete?

The registry lists a primary completion date of 31 Aug 2027 and a study completion date of 31 Aug 2028. The sponsor last updated the record on 9 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.